Published in Clin Pharmacol Ther on April 01, 1997
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther (2011) 3.09
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther (2014) 1.84
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet (2004) 1.51
Treating irritable bowel syndrome: overview, perspective and future therapies. Br J Pharmacol (2004) 0.96
Constipation as an adverse effect of drug use in nursing home patients: an overestimated risk. Br J Clin Pharmacol (1998) 0.93
The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. Eur J Clin Pharmacol (2009) 0.88
Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol (1999) 0.77
[Does genomics determine efficacy of analgesics?]. Schmerz (2005) 0.75
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol (1979) 3.78
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics (2001) 3.05
A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J Invest Dermatol (1999) 2.92
Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem (2001) 2.62
Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther (2001) 2.62
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest (1999) 2.57
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther (2007) 2.48
Bassoon, a novel zinc-finger CAG/glutamine-repeat protein selectively localized at the active zone of presynaptic nerve terminals. J Cell Biol (1998) 2.30
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther (1982) 2.26
Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet (1982) 2.19
Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics (2001) 2.08
Establishment of a typing system for group D streptococci. Zentralbl Bakteriol Mikrobiol Hyg A (1988) 2.07
The teaching and organisation of clinical pharmacology in European medical schools (W.H.O. Working Group on Clinical Pharmacology). Eur J Clin Pharmacol (1990) 2.07
Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem (1995) 2.03
Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet (2001) 2.02
A genome-wide search for linkage to asthma. German Asthma Genetics Group. Genomics (1999) 2.00
Changes in sputum composition between two inductions performed on consecutive days. Thorax (1998) 1.98
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther (2011) 1.98
Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature (1990) 1.96
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol (1999) 1.90
Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol (1998) 1.83
Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study. Aliment Pharmacol Ther (2011) 1.76
Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2. Mech Dev (1998) 1.74
Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg (2000) 1.71
Physiological disposition of verapamil in man. Cardiovasc Res (1976) 1.71
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther (2009) 1.67
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut (2003) 1.66
Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis (2004) 1.65
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics (1998) 1.64
Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant (2008) 1.61
Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol (1975) 1.60
Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet (1991) 1.60
Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos (2001) 1.58
Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol (1991) 1.57
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol (1980) 1.55
Polymorphic drug oxidation in humans. Fed Proc (1984) 1.53
Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain (1998) 1.52
An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Circulation (1994) 1.52
A novel peptide designated PYLa and its precursor as predicted from cloned mRNA of Xenopus laevis skin. EMBO J (1983) 1.51
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics (2001) 1.50
The effect of delta-aminolevulinate on catalase T-messenger RNA levels in delta-aminolevulinate synthase-defective mutants of Saccharomyces cerevisiae. J Biol Chem (1980) 1.50
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther (2000) 1.48
Spin-transistor action via tunable Landau-Zener transitions. Science (2012) 1.47
Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr (1985) 1.46
Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology (1996) 1.42
Yersinia outer protein P of Yersinia enterocolitica simultaneously blocks the nuclear factor-kappa B pathway and exploits lipopolysaccharide signaling to trigger apoptosis in macrophages. J Immunol (2001) 1.41
Is there a genetic factor in flecainide toxicity? BMJ (1988) 1.41
Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol (1984) 1.39
The metabolism of DL-[14C]verapamil in man. Drug Metab Dispos (1979) 1.39
[Extravasal position of central venous catheters despite unsuspicious ECG-guidance]. Anasthesiol Intensivmed Notfallmed Schmerzther (2005) 1.39
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol (1995) 1.39
Role of KCNE1-dependent K+ fluxes in mouse proximal tubule. J Am Soc Nephrol (2001) 1.38
The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J (1985) 1.35
Alkaline phosphatase activity and localization during the murine hair cycle. Br J Dermatol (1994) 1.34
Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J (2007) 1.34
Sequence of preprocaerulein cDNAs cloned from skin of Xenopus laevis. A small family of precursors containing one, three, or four copies of the final product. J Biol Chem (1986) 1.31
Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest (1990) 1.30
Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol (1984) 1.30
Transcription factors Stat3 and Stat5b are present in rat liver nuclei late in an acute phase response and bind interleukin-6 response elements. J Biol Chem (1995) 1.29
A nervous system-specific isotype of the beta subunit of Na+,K(+)-ATPase expressed during early development of Xenopus laevis. Proc Natl Acad Sci U S A (1990) 1.29
The genetic polymorphism of sparteine metabolism. Xenobiotica (1986) 1.27
Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother (2000) 1.27
The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol (1986) 1.26
The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics (1994) 1.25
Drug metabolism in thyroid disease. Clin Pharmacokinet (1976) 1.24
Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol (1981) 1.23
Generation and cyclic remodeling of the hair follicle immune system in mice. J Invest Dermatol (1998) 1.22
Structure of intracellular mature vaccinia virus observed by cryoelectron microscopy. J Virol (1994) 1.21
Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol (1983) 1.21
Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil. Eur J Clin Pharmacol (1984) 1.20
C-terminal regions of Hsp90 are important for trapping the nucleotide during the ATPase cycle. J Mol Biol (2000) 1.18
[Choroid neurilemmoma. Considerations for clinical differential diagnostics]. Klin Monbl Augenheilkd (1976) 1.18
Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eur J Clin Pharmacol (1985) 1.18
CYP3A genetics in drug metabolism. Nat Med (2001) 1.17
Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard. Arzneimittelforschung (1977) 1.17
Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment. Klin Wochenschr (1980) 1.16
Multiple Mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mononuclear cells. Clin Exp Immunol (2007) 1.16
Processing, intracellular transport, and functional expression of endogenous and exogenous alpha-beta 3 Na,K-ATPase complexes in Xenopus oocytes. J Biol Chem (1992) 1.15
Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation. Br J Clin Pharmacol (1986) 1.14
Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand (2008) 1.13
Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics (2000) 1.13
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci (1980) 1.13
The neuron-specific Ca2+-binding protein caldendrin: gene structure, splice isoforms, and expression in the rat central nervous system. Mol Cell Neurosci (2002) 1.12
Chlorinated hydrocarbons in adipose tissue of infants and toddlers: inventory and studies on their association with intake of mothers' milk. Eur J Pediatr (1984) 1.11
P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther (2000) 1.10
Biosynthesis of peptides in the skin of Xenopus laevis: isolation of novel peptides predicted from the sequence of cloned cDNAs. Peptides (1985) 1.09
Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. Eur J Clin Pharmacol (1981) 1.08
Biosynthesis of thyrotropin releasing hormone in the skin of Xenopus laevis: partial sequence of the precursor deduced from cloned cDNA. EMBO J (1984) 1.07
Cpr6 and Cpr7, two closely related Hsp90-associated immunophilins from Saccharomyces cerevisiae, differ in their functional properties. J Biol Chem (2000) 1.07
Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics (2001) 1.06
Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol (1993) 1.06
Gender, values, and intentions to move in rural Thailand. Int Migr Rev (1996) 1.06
Beta(1-->3)-glucan in house dust of German homes: housing characteristics, occupant behavior, and relations with endotoxins, allergens, and molds. Environ Health Perspect (2001) 1.05
Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther (1985) 1.05
Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics (1996) 1.04
The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol (2000) 1.04